PFECL Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26,500.00 |
| 52 Week High | US$30,109.00 |
| 52 Week Low | US$22,200.00 |
| Beta | 0.60 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0.22% |
| 3 Year Change | -36.34% |
| 5 Year Change | n/a |
| Change since IPO | -14.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| PFECL | CL Pharmaceuticals | CL Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 0.2% | 0% | 0% |
Return vs Industry: PFECL exceeded the CL Pharmaceuticals industry which returned -0.8% over the past year.
Return vs Market: PFECL underperformed the CL Market which returned 18.3% over the past year.
Price Volatility
| PFECL volatility | |
|---|---|
| PFECL Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine PFECL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 81,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.
Pfizer Inc. Fundamentals Summary
| PFECL fundamental statistics | |
|---|---|
| Market cap | CL$121.53t |
| Earnings (TTM) | CL$7.50t |
| Revenue (TTM) | CL$59.49t |
16.2x
P/E Ratio2.0x
P/S RatioIs PFECL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFECL income statement (TTM) | |
|---|---|
| Revenue | US$63.63b |
| Cost of Revenue | US$16.42b |
| Gross Profit | US$47.21b |
| Other Expenses | US$39.19b |
| Earnings | US$8.02b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 29, 2025
| Earnings per share (EPS) | 1.41 |
| Gross Margin | 74.19% |
| Net Profit Margin | 12.60% |
| Debt/Equity Ratio | 73.2% |
How did PFECL perform over the long term?
See historical performance and comparisonDividends
7.5%
Current Dividend Yield119%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/26 02:26 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Inc. is covered by 52 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Kerry Holford | Berenberg |
| Luisa Hector | Berenberg |